Transient Blockade of the Inducible Costimulator Pathway Generates Long-term Tolerance to Factor VIII After Nonviral Gene Transfer into Hemophilia A Mice

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2008 Jun 25

PMID 18574023

Citations 35

Authors

Baowei Peng

Peiqing Ye

Bruce R Blazar

Gordon J Freeman

David J Rawlings

Hans D Ochs

Carol H Miao

Affiliations

Soon will be listed here.

Abstract

Formation of inhibitory antibodies is a common problem encountered in clinical treatment for hemophilia. Human factor VIII (hFVIII) plasmid gene therapy in hemophilia A mice also leads to strong humoral responses. We demonstrate that short-term therapy with an anti-ICOS monoclonal antibody to transiently block the inducible costimulator/inducible costimulator ligand (ICOS/ICOSL) signaling pathway led to sustained tolerance to hFVIII in hFVIII plasmid-treated hemophilia A mice and allowed persistent, high-level FVIII functional activity (100%-300% of normal). Anti-ICOS treatment resulted in depletion of ICOS(+)CD4(+) T cells and activation of CD25(+)Foxp3(+) Tregs in the peripheral blood, spleen, and lymph nodes. CD4(+) T cells from anti-ICOS-treated mice did not proliferate in response to hFVIII stimulation and produced high levels of regulatory cytokines, including interleukin-10 and transforming growth factor-beta. Moreover, CD4(+)CD25(+) Tregs from tolerized mice adoptively transferred dominant tolerance in syngeneic hFVIII plasmid-treated hemophilia A mice and reduced the production of antibodies against FVIII. Anti-ICOS-treated mice tolerized to hFVIII generated normal primary and secondary antibody responses after immunization with the T-dependent antigen, bacteriophage Phix 174, indicating maintenance of immune competency. Our data indicate that transient anti-ICOS monoclonal antibody treatment represents a novel single-agent immunomodulatory strategy to overcome the immune responses against transgene product after gene therapy.

Citing Articles

Induction of long-term tolerance to a specific antigen using anti-CD3 lipid nanoparticles following gene therapy.

Chen C, Vander Kooi A, Cavedon A, Cai X, Hoggatt J, Martini P Mol Ther Nucleic Acids. 2023; 34:102043.

PMID: 37920545 PMC: 10618827. DOI: 10.1016/j.omtn.2023.102043.

Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells.

Kaczmarek R, Pineros A, Patterson P, Bertolini T, Perrin G, Sherman A Blood. 2023; 142(3):290-305.

PMID: 37192286 PMC: 10375270. DOI: 10.1182/blood.2022018937.

Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles.

Chen C, Tran D, Cavedon A, Cai X, Rajendran R, Lyle M Mol Ther Nucleic Acids. 2020; 20:534-544.

PMID: 32330871 PMC: 7178004. DOI: 10.1016/j.omtn.2020.03.015.

Molecular Mechanisms of Inhibitor Development in Hemophilia.

Tieu P, Chan A, Matino D Mediterr J Hematol Infect Dis. 2020; 12(1):e2020001.

PMID: 31934311 PMC: 6951349. DOI: 10.4084/MJHID.2020.001.

Platelet Gene Therapy Promotes Targeted Peripheral Tolerance by Clonal Deletion and Induction of Antigen-Specific Regulatory T Cells.

Luo X, Chen J, Schroeder J, Allen K, Baumgartner C, Malarkannan S Front Immunol. 2018; 9:1950.

PMID: 30237796 PMC: 6136275. DOI: 10.3389/fimmu.2018.01950.

References

Dong C, Nurieva R . Regulation of immune and autoimmune responses by ICOS. J Autoimmun. 2003; 21(3):255-60. DOI: 10.1016/s0896-8411(03)00119-7. View

Bi L, Sarkar R, Naas T, Lawler A, Pain J, Shumaker S . Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood. 1996; 88(9):3446-50. View

Chapoval A, Ni J, Lau J, Wilcox R, Flies D, Liu D . B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001; 2(3):269-74. DOI: 10.1038/85339. View

Qian J, Collins M, Sharpe A, HOYER L . Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood. 2000; 95(4):1324-9. View

Maynard C, Harrington L, Janowski K, Oliver J, Zindl C, Rudensky A . Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat Immunol. 2007; 8(9):931-41. DOI: 10.1038/ni1504. View

Rawle F, Shi C, Brown B, McKinven A, Tinlin S, Graham F . Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains. J Gene Med. 2004; 6(12):1358-68. DOI: 10.1002/jgm.624. View

Liang L, Porter E, Sha W . Constitutive expression of the B7h ligand for inducible costimulator on naive B cells is extinguished after activation by distinct B cell receptor and interleukin 4 receptor-mediated pathways and can be rescued by CD40 signaling. J Exp Med. 2002; 196(1):97-108. PMC: 2194020. DOI: 10.1084/jem.20020298. View

Vandendriessche T, Collen D, Chuah M . Gene therapy for the hemophilias. J Thromb Haemost. 2003; 1(7):1550-8. DOI: 10.1046/j.1538-7836.2003.00265.x. View

Shirley P, Andrews J, Tinlin S, Webster S, Cameron C, Hough C . Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood. 2001; 97(1):107-13. DOI: 10.1182/blood.v97.1.107. View

10.

Fields M, Hondowicz B, Metzgar M, Nish S, Wharton G, Picca C . CD4+ CD25+ regulatory T cells inhibit the maturation but not the initiation of an autoantibody response. J Immunol. 2005; 175(7):4255-64. DOI: 10.4049/jimmunol.175.7.4255. View

11.

Kirk A, Harlan D, Armstrong N, Davis T, Dong Y, GRAY G . CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997; 94(16):8789-94. PMC: 23132. DOI: 10.1073/pnas.94.16.8789. View

12.

Andrews J, Kadan M, Gorziglia M, Kaleko M, Connelly S . Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. Mol Ther. 2001; 3(3):329-36. DOI: 10.1006/mthe.2001.0264. View

13.

Herzog R, Fields P, Arruda V, Brubaker J, Armstrong E, McClintock D . Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther. 2002; 13(11):1281-91. DOI: 10.1089/104303402760128513. View

14.

White 2nd G . Gene therapy in hemophilia: clinical trials update. Thromb Haemost. 2001; 86(1):172-7. View

15.

Ochando J, Yopp A, Yang Y, Garin A, Li Y, Boros P . Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. J Immunol. 2005; 174(11):6993-7005. DOI: 10.4049/jimmunol.174.11.6993. View

16.

Kaufmann S . The contribution of immunology to the rational design of novel antibacterial vaccines. Nat Rev Microbiol. 2007; 5(7):491-504. DOI: 10.1038/nrmicro1688. View

17.

Miao C . Recent advances in immune modulation. Curr Gene Ther. 2007; 7(5):391-402. DOI: 10.2174/156652307782151524. View

18.

Dong C, Juedes A, Temann U, Shresta S, Allison J, Ruddle N . ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 2001; 409(6816):97-101. DOI: 10.1038/35051100. View

19.

Izawa A, Yamaura K, Albin M, Jurewicz M, Tanaka K, Clarkson M . A novel alloantigen-specific CD8+PD1+ regulatory T cell induced by ICOS-B7h blockade in vivo. J Immunol. 2007; 179(2):786-96. DOI: 10.4049/jimmunol.179.2.786. View

20.

Chuah M, Schiedner G, Thorrez L, Brown B, Johnston M, Gillijns V . Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood. 2002; 101(5):1734-43. DOI: 10.1182/blood-2002-03-0823. View